This company has been marked as potentially delisted and may not be actively trading. NASDAQ:INFI Infinity Pharmaceuticals (INFI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Infinity Pharmaceuticals Stock (NASDAQ:INFI) 30 days 90 days 365 days Advanced Chart Get INFI alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.01▼$0.1352-Week Range N/AVolume2.48 million shsAverage Volume2.58 million shsMarket Capitalization$726 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. Read More Receive INFI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INFI Stock News HeadlinesRenal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsightMay 7, 2025 | theglobeandmail.comThinking of Trying Collagen? What to Know About the Benefits and DrawbacksSeptember 29, 2024 | msn.comThis Cold War “Accident” Could Unleash New $100 Trillion AI BoomObscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.July 8 at 2:00 AM | Brownstone Research (Ad)Particle Size Analysis Market Size to Reach US$ 816.10 Million by 2032 With an Emerging CAGR of 5.88% | Report by SNS InsiderSeptember 20, 2024 | finance.yahoo.comTriple Negative Breast Cancer Clinical Trials, Treatment Drugs, Pipeline Insights, and Companies 2024September 20, 2024 | theglobeandmail.comCollagen Supplements: What They Can Do for Your Body and What to Watch ForSeptember 18, 2024 | msn.comCollagen Supplements: Benefits, Drawbacks and How to Add It to Your DietAugust 30, 2024 | msn.comWoman shot while driving in South MemphisAugust 20, 2024 | msn.comSee More Headlines INFI Stock Analysis - Frequently Asked Questions How were Infinity Pharmaceuticals' earnings last quarter? Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The biotechnology company earned $0.43 million during the quarter, compared to analysts' expectations of $0.45 million. What other stocks do shareholders of Infinity Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Infinity Pharmaceuticals investors own include Digital Turbine (APPS), ChargePoint (CHPT), CrowdStrike (CRWD), Vuzix (VUZI) and Sangamo Therapeutics (SGMO). Company Calendar Last Earnings11/02/2021Today7/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INFI CIK1113148 Webwww.infi.com Phone(617) 453-1000Fax617-453-1001Employees30Year Founded2000Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.37 million Net Margins-1,593.93% Pretax Margin-1,593.93% Return on EquityN/A Return on Assets-113.02% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$2.59 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / BookN/AMiscellaneous Outstanding Shares90,760,000Free Float81,857,000Market Cap$726 thousand OptionableOptionable Beta1.63 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:INFI) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Infinity Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Infinity Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.